Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 18.1% from a year ago

Total equity stood at $335.83M at the end of Q1 FY2026, up 18.1% from a year earlier and up 38.7% from the prior quarter.

Context

  • Total equity amounted to 44.9% of total assets at the end of Q1 FY2026, down 40.3 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +18.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$335.83M+38.7% QoQ
Last fiscal yearDec 2025
$242.14M-22.5% YoY
Year agoMar 2025
$284.32M+18.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.1%——
1 year-22.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
242.14M USD
Year-over-year change
-22.5%

Total Equity vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's Mar 2026 total equity of $335.83M is the 2nd highest of the 8 companies compared; the peer median is $204.53M.
  • Its year-over-year change of +18.1% is the 3rd highest of 8, against a peer median of -16.1%.
  • Total equity amounts to 44.9% of total assets for ZBIO, versus a peer median of 77.8%.
ZBIO Competitors Peer median
Total Equity for ZBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMVTImmunovant, Inc.Sep 2026$656.95M +26.4%+33.0%86.3%
ZBIOZenas BioPharma, Inc.Mar 2026$335.83M +18.1%—44.9%
UPBUpstream Bio, Inc.Mar 2026$304M -31.8%—95.6%
TRAXFirst Tracks Biotherapeutics IncMar 2026$257.46M -34.3%—88.6%
ANNXAnnexon, Inc.Mar 2026$204.53M -16.1%-2.9%77.8%
ACRSAclaris Therapeutics, Inc.Mar 2026$143.65M -0.3%-19.5%72.3%
QTTBQ32 Bio Inc.Mar 2026$46.31M +1253.8%—72.7%
TLSATiziana Life Sciences LtdDec 2025$52K -98.7%-86.1%0.5%
Peer median (excluding ZBIO) $204.53M-16.1%-11.2%77.8%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents67.21M56.86M319.74M110.64M
Short-term Investments0031.02M232.55M
Net Receivables0000
Inventory0000
Other Current Assets1.24M2.95M5.16M7.98M
Total Current Assets68.44M59.8M355.92M351.17M
Property, Plant & Equipment (Net)1.8M1.01M1.19M1.39M
Goodwill0000
Intangible Assets0000
Long-term Investments00017.27M
Tax Assets0000
Other Non-current Assets4.33M7.36M12.86M13.81M
Total Non-current Assets6.14M8.38M14.05M32.47M
Total Assets74.58M68.18M369.97M383.64M
Account Payables5.82M5.4M17.14M7.11M
Short-term Debt0001.12M
Tax Payables0301K211K0
Deferred Revenue0000
Other Current Liabilities4.33M5.12M8.31M41.23M
Total Current Liabilities25.97M23.26M57.29M62.65M
Long-term Debt020.3M078.64M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities240.09M250.09M00
Total Non-current Liabilities240.9M270.64M218K78.85M
Total Liabilities266.87M293.9M57.51M141.5M
Common Stock004K5K
Retained Earnings(193.28M)(230.4M)(387.39M)(765.13M)
Accumulated OCI(41K)37K194K(64K)
Other Stockholders Equity0000
Minority Interest0000
Total Equity(192.29M)(225.72M)312.46M242.14M
Total Debt1.53M21.11M1M79.96M
Net Debt(65.68M)(35.74M)(318.74M)(30.68M)

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.